Q3 2024 Heron Therapeutics Inc Earnings Call Transcript
Key Points
- Heron Therapeutics Inc (HRTX) reported a significant increase in product gross profit margin to 71% for Q3 2024, up from 42% in the same period in 2023.
- The Crosslink partnership is showing early positive results, with nearly 40,000 ZYNRELEF units ordered since April, contributing approximately $4.4 million in net revenue.
- The company has successfully integrated its business units under the One Heron initiative, leading to increased cooperation and efficiency among teams.
- CINVANTI continues to provide a strong foundational base for the company, maintaining around a 20% market share despite a competitive environment.
- Total acute care net revenues for the quarter were relatively low at $7.4 million, indicating room for growth.
- Net revenues for CINVANTI and [CTOL] were down from Q2, highlighting challenges in maintaining consistent sales in a competitive market.
- The company experienced a net loss of $4.8 million for Q3 2024, although this was an improvement from the previous year.
Total acute care net revenues for the quarter were $7.4 million. [ZYNRELEF] net revenues for the quarter were $6.3 million upon the net revenues for the quarter were $1.1 million.
While we are pleased with our progress, we also knew that we were still transitioning in Q3.
We believe that moving forward, our quarterly growth should start to increase dramatically with the many things we have going on promotionally. These items will not only have an impact on ZYNRELEF but across our entire product portfolio.
Earlier, I spoke about VAN.
And the Nopain Act, both of which will have an impact in 2025.
Right now. We are seeing early results that the Crosslink partnership is beginning to drive growth.
Our team has trained almost 700 crosslink distributors and contractors whose early impact is shown here when a crosslink rep makes a material impact on an account like a key introduction or a trial from a new surgeon.
Our salesforce marked that account as a crosslink account.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
